AB Science announced today that the European Patent Office has issued a Notice of Allowance for a patent relating to methods of treating metastatic hormone-refractory prostate cancer (mCRPC) with its lead compound, masitinib, based on the results of the AB12003 study.

This new European patent secures masitinib's intellectual property in mCRPC until 2042.

Masitinib is used in combination with docetaxel to treat mCRPC patients eligible for chemotherapy, i.e. it is administered directly after treatment of hormone-sensitive metastatic prostate cancer (mHSPC).

Notice of acceptance means that the European Patent Office expects to grant the patent application, EP4175639A1, once certain formal procedural steps have been completed. Once granted, the patent can be maintained in force until May 2042.

Copyright (c) 2023 CercleFinance.com. All rights reserved.